Cleo

Cleo is an enterprise-priced clinical decision support (CDS) platform in the Healthcare AI category, targeting acute care hospitals with AI-driven deterioration detection, sepsis prediction, and capacity management. Pricing is custom per facility and not publicly disclosed; based on comparable platforms in this category (such as Viz.ai and Qventus), costs likely fall in the range of $50,000–$200,000+ per facility per year depending on bed count and modules, though these figures are unconfirmed estimates and should not be treated as actual Cleo pricing. No free or self-serve tier is available.

The platform is built specifically for acute care environments including emergency departments, intensive care units, and inpatient hospital floors. It uses machine learning models trained on clinical data to help care teams identify patients at risk of deterioration, predict sepsis onset, and streamline clinical workflows in high-acuity settings.

Cleo claims to integrate with existing electronic health record (EHR) systems such as Epic and Cerner to ingest real-time patient data including vitals, lab results, medication administration records, and nursing assessments. By analyzing these data streams continuously, it surfaces actionable alerts and risk scores directly within the clinician's existing workflow rather than requiring navigation to a separate application.

Key claimed capabilities include an early warning system for patient deterioration that monitors physiological trends and flags patients whose condition may be declining before traditional scoring systems would trigger an alert. The sepsis prediction module analyzes combinations of vital signs, lab values, and clinical notes to identify patients meeting or approaching sepsis criteria. Cleo also describes capacity management insights to help anticipate patient flow bottlenecks and optimize staffing.

Alert thresholds and model sensitivity can reportedly be configured by each facility's clinical informatics team to balance alert fatigue against detection sensitivity. Cleo states that it provides transparency into how risk scores are generated, showing contributing factors for each alert.

What distinguishes Cleo from alternatives is its attempt to unify three capabilities — real-time patient deterioration detection, sepsis prediction, and capacity management — within a single platform purpose-built for acute care. Competitors typically specialize in one of these areas: Qventus focuses on operational throughput and scheduling rather than clinical deterioration, Viz.ai and Aidoc concentrate on imaging-based detection for specific conditions, and Epic's built-in Sepsis Model provides only sepsis scoring without broader deterioration monitoring or capacity tools. For hospitals wanting a consolidated clinical surveillance layer across these domains without assembling multiple point solutions, Cleo positions itself as a single-vendor alternative — though this consolidation advantage must be weighed against the larger install bases and longer track records of established competitors.

Important note: Cleo is a relatively new entrant in the clinical decision support market and independent verification of its claims, customer base, and clinical validation is extremely limited as of this writing. Its website (cleohealth.io) is not a widely recognized domain in the healthcare IT space. No peer-reviewed studies, named customer references, specific outcome statistics, or FDA clearance documentation are publicly available. The pricing figures in this listing are estimates extrapolated from comparable platforms, not confirmed by Cleo. All feature descriptions and integration claims are sourced from vendor-provided materials and have not been independently audited. Prospective buyers should independently verify all vendor claims, request verifiable references from current customers, review any available clinical validation data, confirm FDA regulatory status, and conduct local validation studies before committing.